{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:01Z","timestamp":1786480261601,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea grant","doi-asserted-by":"crossref","award":["2021R1A2C2095096"],"award-info":[{"award-number":["2021R1A2C2095096"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39413-7","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T13:21:01Z","timestamp":1771248061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of early vedolizumab trough levels with clinical, biochemical, endoscopic response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases"],"prefix":"10.1038","volume":"16","author":[{"given":"Kyuwon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Ran","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghwan","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Seung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Wook","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Wook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Sik","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jae","family":"Myung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byong Duk","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"39413_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","volume":"153","author":"DJ Erle","year":"1994","unstructured":"Erle, D. J. et al. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J. Immunol. 153, 517\u2013528 (1994).","journal-title":"J. Immunol."},{"key":"39413_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler, D. et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 330, 864\u2013875. https:\/\/doi.org\/10.1124\/jpet.109.153973 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"39413_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl. J. Med. 369, 699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1215734 (2013).","journal-title":"N Engl. J. Med."},{"key":"39413_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn, W. J. et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl. J. Med. 369, 711\u2013721. https:\/\/doi.org\/10.1056\/NEJMoa1215739 (2013).","journal-title":"N Engl. J. Med."},{"key":"39413_CR5","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","volume":"11","author":"M Rosario","year":"2017","unstructured":"Rosario, M. et al. Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or crohn\u2019s disease. J. Crohns Colitis. 11, 921\u2013929. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx021 (2017).","journal-title":"J. Crohns Colitis"},{"key":"39413_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/apt.14548","volume":"47","author":"W Yacoub","year":"2018","unstructured":"Yacoub, W. et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment. Pharmacol. Ther. 47, 906\u2013912. https:\/\/doi.org\/10.1111\/apt.14548 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"39413_CR7","doi-asserted-by":"publisher","unstructured":"Dreesen, E. et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 16, 1937\u20131946. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.040 (2018).","DOI":"10.1016\/j.cgh.2018.04.040"},{"key":"39413_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/apt.15113","volume":"49","author":"MT Osterman","year":"2019","unstructured":"Osterman, M. T. et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment. Pharmacol. Ther. 49, 408\u2013418. https:\/\/doi.org\/10.1111\/apt.15113 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"39413_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/ibd\/izy272","volume":"25","author":"B Al-Bawardy","year":"2019","unstructured":"Al-Bawardy, B. et al. Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease. Inflamm. Bowel Dis. 25, 580\u2013586. https:\/\/doi.org\/10.1093\/ibd\/izy272 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"39413_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5217\/ir.2019.09167","volume":"19","author":"H Okamoto","year":"2021","unstructured":"Okamoto, H., Dirks, N. L., Rosario, M., Hori, T. & Hibi, T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn\u2019s disease. Intest Res. 19, 95\u2013105. https:\/\/doi.org\/10.5217\/ir.2019.09167 (2021).","journal-title":"Intest Res."},{"key":"39413_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5217\/ir.2019.09160","volume":"19","author":"R Banerjee","year":"2021","unstructured":"Banerjee, R. et al. Efficacy and safety of vedolizumab in Crohn\u2019s disease in patients from Asian countries in the GEMINI 2 study. Intest Res. 19, 83\u201394. https:\/\/doi.org\/10.5217\/ir.2019.09160 (2021).","journal-title":"Intest Res."},{"key":"39413_CR12","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41598-023-28566-4","volume":"13","author":"D Anbarserry","year":"2023","unstructured":"Anbarserry, D. et al. The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease. Sci. Rep. 13, 1771. https:\/\/doi.org\/10.1038\/s41598-023-28566-4 (2023).","journal-title":"Sci. Rep."},{"key":"39413_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/ecco-jcc\/jjz041","volume":"13","author":"RC Ungaro","year":"2019","unstructured":"Ungaro, R. C. et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J. Crohns Colitis. 13, 963\u2013969. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz041 (2019).","journal-title":"J. Crohns Colitis"},{"key":"39413_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner, D. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for Treat-to-Target strategies in IBD. Gastroenterology 160, 1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031 (2021).","journal-title":"Gastroenterology"},{"key":"39413_CR15","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","volume":"15","author":"N Williet","year":"2017","unstructured":"Williet, N. et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin. Gastroenterol. Hepatol. 15, 1750\u20131757e1753. https:\/\/doi.org\/10.1016\/j.cgh.2016.11.023 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"39413_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ecco-jcc\/jjw176","volume":"11","author":"S Vermeire","year":"2017","unstructured":"Vermeire, S. et al. Long-term efficacy of vedolizumab for Crohn\u2019s disease. J. Crohns Colitis. 11, 412\u2013424. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw176 (2017).","journal-title":"J. Crohns Colitis"},{"key":"39413_CR17","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/ibd\/izy171","volume":"24","author":"E Shmidt","year":"2018","unstructured":"Shmidt, E. et al. Predictors and management of loss of response to vedolizumab in inflammatory bowel disease. Inflamm. Bowel Dis. 24, 2461\u20132467. https:\/\/doi.org\/10.1093\/ibd\/izy171 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"39413_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","volume":"16","author":"B Ungar","year":"2018","unstructured":"Ungar, B. et al. Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 16, 697\u2013705. https:\/\/doi.org\/10.1016\/j.cgh.2017.11.050 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"39413_CR19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli, M. H. et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and Meta-Analysis. Am. J. Gastroenterol. 110, 802\u2013819. https:\/\/doi.org\/10.1038\/ajg.2015.120 (2015). quiz 820","journal-title":"Am. J. Gastroenterol."},{"key":"39413_CR20","doi-asserted-by":"publisher","first-page":"5a","DOI":"10.1155\/2005\/269076","volume":"19 Suppl A","author":"MS Silverberg","year":"2005","unstructured":"Silverberg, M. S. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19 Suppl A, 5a\u201336a. https:\/\/doi.org\/10.1155\/2005\/269076 (2005).","journal-title":"Can. J. Gastroenterol."},{"key":"39413_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","volume":"14","author":"A Amiot","year":"2016","unstructured":"Amiot, A. et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 14, 1593\u20131601. https:\/\/doi.org\/10.1016\/j.cgh.2016.02.016 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"39413_CR22","doi-asserted-by":"publisher","first-page":"e0179266","DOI":"10.1371\/journal.pone.0179266","volume":"12","author":"K Oh","year":"2017","unstructured":"Oh, K. et al. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn\u2019s disease. PLoS One. 12, e0179266. https:\/\/doi.org\/10.1371\/journal.pone.0179266 (2017).","journal-title":"PLoS One"},{"key":"39413_CR23","doi-asserted-by":"publisher","unstructured":"Kristensen, V., R\u00f8seth, A., Ahmad, T., Skar, V. & Moum, B. Fecal calprotectin: A reliable predictor of mucosal healing after treatment for active ulcerative colitis. Gastroenterol. Res. Pract. 2017 (2098293). https:\/\/doi.org\/10.1155\/2017\/2098293 (2017).","DOI":"10.1155\/2017\/2098293"},{"key":"39413_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","volume":"157","author":"S Danese","year":"2019","unstructured":"Danese, S. et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn\u2019s disease. Gastroenterology 157, 1007\u20131018. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.038 (2019).","journal-title":"Gastroenterology"},{"key":"39413_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","volume":"132","author":"G D\u2019Haens","year":"2007","unstructured":"D\u2019Haens, G. et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132, 763\u2013786. https:\/\/doi.org\/10.1053\/j.gastro.2006.12.038 (2007).","journal-title":"Gastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39413-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:39:30Z","timestamp":1773826770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39413-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39413"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39413-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BDY reports consulting fees from AbbVie Korea, BMS Pharmaceutical Korea Ltd., Celltrion, Chong Kun Dang Pharm, CJ Red BIO, Curacle, Daewoong Pharm, Dong-A ST, Ferring Korea, Hanmi Pharmaceutical, Imscout, IQVIA, Johnson & Johnson, Johnson & Johnson Korea, Jeil Pharmaceutical Co., Kangstem Biotech, Korea Otsuka Pharm, Korea United Pharm, Lilly Korea, Medtronic Korea, NanoEntek, ORGANOIDSCIENCES Ltd., Pfizer Korea, Samsung Bioepis, Takeda, Takeda Korea and Yuhan; speaker fees from AbbVie Korea, BMS Pharmaceutical Korea Ltd., Celltrion, Cornerstones Health, Curacle, Daewoong Pharm, Eisai Korea, Ferring Korea, IQVIA, Johnson & Johnson Korea, Pfizer Korea, Samsung Bioepis, and Takeda Korea; and research support from Celltrion and Pfizer Korea. None of these is relevant to this article. The other authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9289"}}